Novartis case in India
DavidLegge (Talk | contribs) |
DavidLegge (Talk | contribs) |
||
| Line 6: | Line 6: | ||
The Novartis case. See documentation at Berne Declaration [[http://www.evb.ch/en/p25012749.html]] | The Novartis case. See documentation at Berne Declaration [[http://www.evb.ch/en/p25012749.html]] | ||
| + | |||
| + | ''' MSF Petition regarding Novartis ''' <br /> | ||
| + | http://www.msf.org/petition_india/can_eng.html | ||
| + | |||
| + | '''US activists try to deliver coffin to Novartis over Indian patent case''' <br /> | ||
| + | 29 Jan: WASHINGTON (AFP) - Non-governmental groups tried to deliver a mini coffin to Swiss pharmaceuticals giant Novartis to protest legal action aiming to overturn a ban on a drug patent application in India. <br /> | ||
| + | http://news.yahoo.com/s/afp/20070129/hl_afp/usindiapharmacompany_070129215623 | ||
| + | |||
| + | '''Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines''' | ||
| + | Janice M. Mueller ''NEJM'' Volume 356:541-543 | ||
| + | |||
| + | In August and September 2006, patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations (NGOs) converged on the offices of Novartis in Mumbai, India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate. Gleevec (spelled Glivec outside the United States) is used to treat chronic myeloid leukemia, and Novartis has patented the drug in 35 countries. The protesters also decried the drug's high price: Novartis sells it in India (where only 5% of people have private health insurance) for $26,000 per year; generic-drug manufacturers offer the drug at less than one tenth that price.... | ||
| + | |||
| + | |||
[[Intellectual Property and Pharmaceuticals|Back to IP home]] | [[Intellectual Property and Pharmaceuticals|Back to IP home]] | ||
Revision as of 07:21, 9 July 2007
Background to the early development of IP in India and process-only patenting
Early pressure to change (marketing approval).
Accession to WTO and TRIPS from 2005 and requirement to introduce product patenting as well as process patenting.
The Novartis case. See documentation at Berne Declaration [[1]]
MSF Petition regarding Novartis
http://www.msf.org/petition_india/can_eng.html
US activists try to deliver coffin to Novartis over Indian patent case
29 Jan: WASHINGTON (AFP) - Non-governmental groups tried to deliver a mini coffin to Swiss pharmaceuticals giant Novartis to protest legal action aiming to overturn a ban on a drug patent application in India.
http://news.yahoo.com/s/afp/20070129/hl_afp/usindiapharmacompany_070129215623
Taking TRIPS to India — Novartis, Patent Law, and Access to Medicines Janice M. Mueller NEJM Volume 356:541-543
In August and September 2006, patients with cancer, lawyers for patient advocacy groups, and representatives of nongovernmental organizations (NGOs) converged on the offices of Novartis in Mumbai, India, to protest the company's efforts to obtain an Indian patent on Gleevec, the company's brand-name version of imatinib mesylate. Gleevec (spelled Glivec outside the United States) is used to treat chronic myeloid leukemia, and Novartis has patented the drug in 35 countries. The protesters also decried the drug's high price: Novartis sells it in India (where only 5% of people have private health insurance) for $26,000 per year; generic-drug manufacturers offer the drug at less than one tenth that price....
